Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury: An observational cohort study

Critical Care

Volumn 15, Issue 4, 2011, Pages

  Haase Fielitz, Anja ^a   Mertens, Peter R ^a   Plaß, Michael ^b   Kuppe, Hermann ^b   Hetzer, Roland ^b   Westerman, Mark ^c   Ostland, Vaughn ^c   Prowle, John R ^d   Bellomo, Rinaldo ^d   Haase, Michael ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c Intrinsic LifeSciences LLC   (United States)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; HEPCIDIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CARDIOPULMONARY BYPASS ASSOCIATED ACUTE KIDNEY INJURY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; POSTOPERATIVE COMPLICATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; URINALYSIS; URINARY EXCRETION; AGED; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; URINE;

ACUTE KIDNEY INJURY; AGED; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 79961110645     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10339     Document Type: Article

References (43)

1. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005, 16:3365-3370. 10.1681/ASN.2004090740, 16177006.
2. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, . Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818. 10.1001/jama.294.7.813, 16106006, Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators.
3. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006, 1:19-32. 10.2215/CJN.01420406, 17699187.
4. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238. 10.1016/S0140-6736(05)74811-X, 15811456.
5. Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, Raman J, Jeevanandam V, O'Connor MF, Devarajan P, Bonventre JV, Murray PT. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010, 5:2154-2165. 10.2215/CJN.00740110, 20798258.
6. Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D, Haase M. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery: a prospective cohort study. Crit Care Med 2009, 37:553-560. 10.1097/CCM.0b013e318195846e, 19114878.
7. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003, 14:2534-2543. 10.1097/01.ASN.0000088027.54400.C6, 14514731.
8. Devarajan P, Mishra J, Supavekin S, Patterson LT, Potter SS. Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab 2003, 80:365-376. 10.1016/j.ymgme.2003.09.012, 14654349.
9. Smith MP, Banks RE, Wood SL, Lewington AJ, Selby PJ. Application of proteomic analysis to the study of renal diseases. Nat Rev Nephrol 2009, 5:701-712. 10.1038/nrneph.2009.183, 19859072.
10. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007, 18:394-400. 10.1681/ASN.2006070802, 17229910.
11. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loréal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001, 276:7811-7819. 10.1074/jbc.M008923200, 11113132.
12. Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem 2002, 277:37597-37603. 10.1074/jbc.M205305200, 12138110.
13. Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol 2005, 184:361-370. 10.1677/joe.1.05729, 15684344.
14. Ho J, Lucy M, Krokhin O, Hayglass K, Pascoe E, Darroch G, Rush D, Nickerson P, Rigatto C, Reslerova M. Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study. Am J Kidney Dis 2009, 53:584-595. 10.1053/j.ajkd.2008.10.037, 19070948.
15. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100. 10.1111/j.1523-1755.2005.00365.x, 15882252.
16. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, . Chronic Kidney Disease Epidemiology Collaboration Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007, 53:766-772. 10.1373/clinchem.2006.077180, 17332152, Chronic Kidney Disease Epidemiology Collaboration.
17. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, . Acute Dialysis Quality Initiative workgroup Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs. The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212. 10.1186/cc2872, 522841, 15312219, Acute Dialysis Quality Initiative workgroup.
18. Englberger L, Suri RM, Li Z, Casey ET, Daly RC, Dearani JA, Schaff HV. Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery. Crit Care 2011, 15:R16. 10.1186/cc9960, 21232094.
19. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, . STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457. 10.1016/S0140-6736(07)61602-X, 18064739, STROBE Initiative.
20. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008, 112:4292-4297. 10.1182/blood-2008-02-139915, 18689548.
21. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988, 240:1285-1293. 10.1126/science.3287615, 3287615.
22. Youden WJ. Index for rating diagnostic tests. Cancer 1950, 3:32-35. 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3, 15405679.
23. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. 10.1002/sim.2929, 17569110.
24. Argalious M, Xu M, Sun Z, Smedira N, Koch CG. Preoperative statin therapy is not associated with a reduced incidence of postoperative acute kidney injury after cardiac surgery. Anesth Analg 2010, 111:324-330. 10.1213/ANE.0b013e3181d8a078, 20375302.
25. Haase M, Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Reade MC, Bagshaw SM, Seevanayagam N, Seevanayagam S, Doolan L, Buxton B, Dragun D. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med 2009, 37:39-47. 10.1097/CCM.0b013e318193216f, 19112278.
26. van Eijk LT, Kroot JJ, Tromp M, van der Hoeven JG, Swinkels DW, Pickkers P. Inflammation-induced hepcidin-25 is associated with the development of anemia in septic patients: an observational study. Crit Care 2011, 15:R9. 10.1186/cc9408, 21219610.
27. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest 2010, 120:4466-4477. 10.1172/JCI41717, 2993583, 21099112.
28. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463. 10.1182/blood-2002-10-3235, 12433676.
29. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008, 28:115-121. 10.1159/000109968, 17943020.
30. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB. Hepcidin: a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1051-1056. 10.2215/CJN.05931108, 2689881, 19406957.
31. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276:7806-7810. 10.1074/jbc.M008922200, 11113131.
32. Hamada Y, Fukagawa M. Is hepcidin the star player in iron metabolism in chronic kidney disease?. Kidney Int 2009, 75:873-874. 10.1038/ki.2009.46, 19367309.
33. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110:1037-1044. 151151, 12370282.
34. Piperno A, Galimberti S, Mariani R, Pelucchi S, Ravasi G, Lombardi C, Bilo G, Revera M, Giuliano A, Faini A, Mainini V, Westerman M, Ganz T, Valsecchi MG, Mancia G, Parati G, . HIGHCARE investigators Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood 2011, 117:2953-2959. 10.1182/blood-2010-08-299859, 21149632, HIGHCARE investigators.
35. Hoppe M, Lönnerdal B, Hossain B, Olsson S, Nilsson F, Lundberg PA, Rödjer S, Hulthén L. Hepcidin, interleukin-6 and hematological iron markers in males before and after heart surgery. J Nutr Biochem 2009, 20:11-16. 10.1016/j.jnutbio.2007.11.008, 18495462.
36. Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Novel urine hepcidin assay by mass spectrometry. Blood 2005, 106:3268-3270. 10.1182/blood-2005-05-1873, 16030189.
37. Reslerova M, Rigatto C. In reply to 'Hepcidin levels in acute kidney injury following cardiopulmonary bypass grafting'. Am J Kidney Dis 2009, 54:980.
38. Laarakkers CM, Wetzels JF, Swinkels DW. Hepcidin levels in acute kidney injury following cardiopulmonary bypass grafting. Am J Kidney Dis 2009, 54:979-980. 10.1053/j.ajkd.2009.06.045, 19853199.
39. Huybregts RA, Morariu AM, Rakhorst G, Spiegelenberg SR, Romijn HW, de Vroege R, van Oeveren W. Attenuated renal and intestinal injury after use of a mini-cardiopulmonary bypass system. Ann Thorac Surg 2007, 83:1760-1766. 10.1016/j.athoracsur.2007.02.016, 17462395.
40. Tang AT, Knott J, Nanson J, Hsu J, Haw MP, Ohri SK. A prospective randomized study to evaluate the renoprotective action of beating heart coronary surgery in low risk patients. Eur J Cardiothorac Surg 2002, 22:118-123. 10.1016/S1010-7940(02)00220-8, 12103384.
41. Loef BG, Epema AH, Navis G, Ebels T, van Oeveren W, Henning RH. Off-pump coronary revascularization attenuates transient renal damage compared with on-pump coronary revascularization. Chest 2002, 121:1190-1194. 10.1378/chest.121.4.1190, 11948052.
42. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D'Agati V, Devarajan P, Barasch J. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005, 115:610-621. 548316, 15711640.
43. Prowle JR, Ostland V, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Bagshaw SM, Haase-Fielitz A, Haase M, Westerman M, Bellomo R. Greater increase in urinary hepcidin predicts protection from acute kidney injury after cardiopulmonary bypass. Nephrol Dial Transpl